These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

824 related items for PubMed ID: 18022078

  • 1. Post-transplant baseline FEV1 and the development of bronchiolitis obliterans syndrome: an important confounder?
    Burton CM, Iversen M, Mortensen J, Carlsen J, Andersen CB, Milman N, Scheike T.
    J Heart Lung Transplant; 2007 Nov; 26(11):1127-34. PubMed ID: 18022078
    [Abstract] [Full Text] [Related]

  • 2. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1.
    Burton CM, Iversen M, Carlsen J, Mortensen J, Andersen CB, Steinbrüchel D, Scheike T.
    J Heart Lung Transplant; 2009 Sep; 28(9):888-93. PubMed ID: 19716040
    [Abstract] [Full Text] [Related]

  • 3. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.
    Heng D, Sharples LD, McNeil K, Stewart S, Wreghitt T, Wallwork J.
    J Heart Lung Transplant; 1998 Dec; 17(12):1255-63. PubMed ID: 9883768
    [Abstract] [Full Text] [Related]

  • 4. Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome.
    Burton CM, Carlsen J, Mortensen J, Andersen CB, Milman N, Iversen M.
    J Heart Lung Transplant; 2007 Jul; 26(7):681-6. PubMed ID: 17613397
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction.
    Sato M, Waddell TK, Wagnetz U, Roberts HC, Hwang DM, Haroon A, Wagnetz D, Chaparro C, Singer LG, Hutcheon MA, Keshavjee S.
    J Heart Lung Transplant; 2011 Jul; 30(7):735-42. PubMed ID: 21419659
    [Abstract] [Full Text] [Related]

  • 7. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation.
    Glanville AR, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA.
    Am J Respir Crit Care Med; 2008 May 01; 177(9):1033-40. PubMed ID: 18263803
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation.
    Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T.
    Transplantation; 2008 Jan 15; 85(1):36-41. PubMed ID: 18192909
    [Abstract] [Full Text] [Related]

  • 11. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation.
    Davis RD, Lau CL, Eubanks S, Messier RH, Hadjiliadis D, Steele MP, Palmer SM.
    J Thorac Cardiovasc Surg; 2003 Mar 15; 125(3):533-42. PubMed ID: 12658195
    [Abstract] [Full Text] [Related]

  • 12. Seasonal onset of bronchiolitis obliterans syndrome in lung transplant recipients.
    Hohlfeld J, Niedermeyer J, Hamm H, Schäfers HJ, Wagner TO, Fabel H.
    J Heart Lung Transplant; 1996 Sep 15; 15(9):888-94. PubMed ID: 8889984
    [Abstract] [Full Text] [Related]

  • 13. The impact of cytolytic therapy on bronchiolitis obliterans syndrome.
    Date H, Lynch JP, Sundaresan S, Patterson GA, Trulock EP.
    J Heart Lung Transplant; 1998 Sep 15; 17(9):869-75. PubMed ID: 9773858
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of the 6min walk test in bronchiolitis obliterans syndrome.
    Nathan SD, Shlobin OA, Reese E, Ahmad S, Fregoso M, Athale C, Barnett SD.
    Respir Med; 2009 Dec 15; 103(12):1816-21. PubMed ID: 19682883
    [Abstract] [Full Text] [Related]

  • 15. Are heart-lung transplant recipients protected from developing bronchiolitis obliterans syndrome?
    Moffatt-Bruce SD, Karamichalis J, Robbins RC, Whyte RI, Theodore J, Reitz BA.
    Ann Thorac Surg; 2006 Jan 15; 81(1):286-91; discussion 291. PubMed ID: 16368382
    [Abstract] [Full Text] [Related]

  • 16. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome.
    Valentine VG, Gupta MR, Walker JE, Seoane L, Bonvillain RW, Lombard GA, Weill D, Dhillon GS.
    J Heart Lung Transplant; 2009 Feb 15; 28(2):163-9. PubMed ID: 19201342
    [Abstract] [Full Text] [Related]

  • 17. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients.
    Liu V, Dhillon GS, Weill D.
    Transpl Infect Dis; 2010 Feb 15; 12(1):38-44. PubMed ID: 19761558
    [Abstract] [Full Text] [Related]

  • 18. Single-lung transplantation: does side matter?
    Tsagkaropoulos S, Belmans A, Verleden GM, Coosemans W, Decaluwe H, De Leyn P, Nafteux P, Van Raemdonck D.
    Eur J Cardiothorac Surg; 2011 Aug 15; 40(2):e83-92. PubMed ID: 21497108
    [Abstract] [Full Text] [Related]

  • 19. Association between donor MBL promoter haplotype and graft survival and the development of BOS after lung transplantation.
    Munster JM, van der Bij W, Breukink MB, van der Steege G, Zuurman MW, Hepkema BG, Verschuuren EA, van Son WJ, Seelen MA.
    Transplantation; 2008 Dec 27; 86(12):1857-63. PubMed ID: 19104434
    [Abstract] [Full Text] [Related]

  • 20. Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients.
    Lama VN, Murray S, Lonigro RJ, Toews GB, Chang A, Lau C, Flint A, Chan KM, Martinez FJ.
    Am J Respir Crit Care Med; 2007 Jun 01; 175(11):1192-8. PubMed ID: 17347496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.